Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL +9.38% EV-to-OCF is -6.87 as of Aug. 05, 2026. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Control Bionics ranks better than 76.91% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Control Bionics's Enterprise Value is A$28.35 Mil.
Control Bionics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.13 Mil. Therefore, Control Bionics's EV-to-OCF for today is -6.87.
The historical rank and industry rank for Control Bionics's EV-to-OCF or its related term are showing as below:
ASX:CBL'
s EV-to-OCF Range Over the Past 10 Years
Min: -8.38 Med: -1.82 Max: 1.12
Current: -6.76
During the past 6 years, the highest EV-to-OCF of Control Bionics was 1.12. The lowest was -8.38. And the median was -1.82.
ASX:CBL's EV-to-OCF is ranked better than 76.91% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.78
vs ASX:CBL: -6.76
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Control Bionics's PE Ratio (TTM) for today is calculated as:
Control Bionics's share price for today is A$0.07.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Control Bionics EV-to-OCF Related Terms
Control Bionics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Control Bionics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Control Bionics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Control Bionics's EV-to-OCF falls into.
Control Bionics's current Enterprise Value is A$28.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Control Bionics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a EV-to-OCF of -6.87 as of Aug. 05, 2026. According to the industry distribution chart, Control Bionics ranks #197 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 23.1%.
Is Control Bionics' EV-to-OCF too high?
Control Bionics' current EV-to-OCF is -6.87. Based on the distribution chart, Control Bionics ranks #197 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does Control Bionics' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #197 out of 853 companies for EV-to-OCF. This places Control Bionics in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.78. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.78, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current EV-to-OCF is -6.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 133.3% above its estimated fair value. The current EV-to-OCF is -6.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current EV-to-OCF is -6.87 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
